Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
News Sep 19, 2016
Why do some foodborne bacteria make us sick? A paper published Sept. 16 in the journal Science has found that pathogens in the intestinal tract cause harm because they benefit from immune system responses designed to repair the very damage to the intestinal lining caused by the bacteria in the first place.
“The finding is important because it explains how some enteric pathogens can manipulate mammalian cells to get the oxygen they need to breathe,” said Andreas Bäumler, a professor of medical microbiology and immunology at UC Davis School of Medicine and lead author of the study. “It also offers new insight into developing strategies targeting the metabolism of the intestinal lining to prevent the expansion of harmful bacteria in the gut, a situation that is exacerbated by the overuse of antibiotics.”
A healthy large intestine is mostly free of oxygen, and the beneficial microbes residing there thrive in this anaerobic environment. In contrast, enteric pathogens, such as Escherichia coli in humans or Citrobacter rodentium in mice, need oxygen to survive.
Bäumler’s team discovered how these pathogens change the gut environment to favor their own growth.
“Enteric pathogens deploy virulence factors that damage the intestinal lining and cause diarrhea,” Bäumler said. “To repair the damage, the body accelerates the division of epithelial cells that form the intestinal lining, which brings immature cells to the mucosal surface. These new cells contain more oxygen and wind up increasing oxygen levels in the large bowel, creating an environment that allows gut pathogens like E. coli to outcompete the anaerobic-loving resident microbes.”
Bäumler’s research has important implications for developing new treatment strategies that target factors that compromise the intestinal-lining function or bolster microbiota composition to offer either resistance or assistance to invading pathogens.
“The rise of antibiotic-resistant strains of bacteria has become a major public health threat worldwide, Bäumler said. “As more bacterial strains do not respond to the drugs designed to kill them, the advances made in treating infectious diseases over the last 50 years are in jeopardy.”
This year, the Centers for Disease Control and Prevention identified three drug-resistant organisms – Clostridium difficile, Carbapenem enterobacteriaceae and Neisseria gonorrhoeae – as requiring urgent attention, and in May, a report commissioned by the UK government predicted that by 2050 antimicrobial-resistant infections could claim 10 million lives a year and cost up to $100 trillion from the global economy.
Understanding how gut pathogens manipulate the body’s natural defense mechanisms to grab hold and contribute to abnormal states within and beyond the GI tract is a burgeoning area of research at UC Davis. Scientists from schools and colleges across the campus are investigating antibiotic resistance as well as the influence that gut-flora imbalances have on many conditions, including brain health and behavior, obesity, inflammatory bowel disease, irritable bowel syndrome, GI cancers, cardiovascular disease, fatty liver disease, autism, arthritis and asthma.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE